Ageing and cancer
PRINCIPAL INVESTIGATORS
- Joan Maria Viñals Viñals
- Juan Jesus Martin Liberal
CLINICAL RESEARCHERS
- Rosa Maria Penin Mosquera
- Diana Perez Sidelnikova
POSTDOCTORAL RESEARCHERS
- Marta Lopez Cerda
- Laura Lorenzo Sanz
PREDOCTORAL RESEARCHERS
- Natalia Perez De Gracia Velazquez
CANCER
ONCOBELL
Scientific production
13
PAPERS
Average IF: 7,23
9
LED PAPERS
Average IF: 6,72
4 PUBLICATIONS IN FIRST DECILE
6 PUBLICATIONS IN FIRST QUARTILE
11 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Lorenzo Sanz,L;Lopez Cerda,M;da Silva Diz,V;Artés,MH;Llop,S;Penin,RM;Bermejo,JO et al, Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma, Nat Commun, 2024;15(1):5352-5352, doi:10.1038/s41467-024-49718-8
- Lopez Cerda,M;Lorenzo Sanz,L;da Silva Diz,V;Llop,S;Penin,RM;Bermejo,JO;Haas,RD et al, IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinoma, J. Exp. Clin. Cancer Res., 2024;43(1):211-211, doi:10.1186/s13046-024-03119-3
- D’Alise,AM;Leoni,G;Cotugno,G;Siani,L;Vitale,R;Ruzza,V;Garzia,I et al, Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses, Clin Cancer Res, 2024;30(11):2412-2423, doi:10.1158/1078-0432.CCR-23-3940
- Márquez Rodas,I;Alvarez,A;Arance,A;Valduvieco,I;Berciano Guerrero,MA;Delgado,R;Soria,A et al, Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study), Neuro-Oncology, 2024;doi:10.1093/neuonc/noae116
- Gamissans,M;Muntaner Virgili,C;Penín,RM;Marcoval,J, Characteristics of Spontaneous Regression in Merkel Cell Carcinoma: A Retrospective Analysis of Patient and Tumor Features., Clin Exp Dermatol, 2024;doi:10.1093/ced/llae508
Research highlights
PROJECTS
1 Granted competitive projects
7 Ongoing competitive projects
5 Started clinical trials
13 Ongoing clinical trials
3 Ongoing non competitive projects
NETWORKS
EuroPDX
AGAUR SGR GRC
Selected projects
- PID2020-113495RB-I00. Estudio de nuevas estrategias terapéuticas para suprimir la resistencia a terapias basadas en el bloqueo de los puntos de control inmunitarios (ICB) en cSCC y HNSCCs avanzados. Ministerio de Ciencia e Innovación. Budget: 223.850€. 2021-2024. PI: MUÑOZ MORUNO, PURIFICACION.
- PID2023-149132OB-I00. FACTORES Y MECANISMOS IMPLICADOS EN LA RESISTENCIA A INHIBIDORES DE IMMUNE CHECKPOINT (ICIs) EN cSCC: INFLUENCIA DE UN MICROAMBIENTE TUMORAL ENVEJECIDO. Ministerio de Ciencia e Innovación. Budget: 300.000€. 2024-2027. PI: MUÑOZ MORUNO, PURIFICACION.
- ICI21/00110. Tratamiento con TILs en tumores avanzados con alteraciones del complejo SWI/SNF: El estudio TILTS. Instituto de Salud Carlos III (ISCIII). Budget: 1.081.914,72€. 2022-2025. PI: MARTIN LIBERAL, JUAN JESUS.
- OMX-0407-101. A PHASE I/IB DOSE ESCALATION AND COHORT EXPANSION STUDY OF OMX-0407 A SALT-INDUCIBLE KINASE INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE SOLID TUMOURS. IOMX THERAPEUTICS AG. Budget: 211.084€. 2024- . PI: MARTIN LIBERAL, JUAN JESUS.
- 2021 SGR 00769. “”Nuevas terapias para el tratamiento de cáncer de piel
Novel therapies for skin cancer treatment””. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 40.000€. 2022-2025. PI: MUÑOZ MORUNO, PURIFICACION /MARTIN LIBERAL, JUAN JESUS.